Related Experiment Video
Updated: Nov 7, 2025
12:43
On-Chip Endothelial Inflammatory Phenotyping
Published on: July 21, 2012
11.1K
13C Metabolic Flux Analysis Indicates Endothelial Cells Attenuate Metabolic Perturbations by Modulating TCA Activity
Bilal Moiz1, Jonathan Garcia2, Sarah Basehore2
1Fischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
Metabolites
|April 30, 2021
Summary
Targeted inhibition of specific metabolic pathways in endothelial cells alters cellular metabolism. Understanding these systemic effects is crucial for developing new cardiovascular disease therapeutics.
Area of Science:
- Endothelial cell metabolism
- Cardiovascular disease research
- Metabolic pathway analysis
Background:
- Disrupted endothelial metabolism contributes to endothelial dysfunction and cardiovascular disease.
- Targeted metabolic inhibitors offer therapeutic potential, but their systemic effects on endothelial metabolism are not well understood.
- Human umbilical vein endothelial cells (HUVECs) are a key model for studying endothelial function.
Purpose of the Study:
- To investigate the impact of targeted inhibition of the polyol, pentose phosphate, and hexosamine biosynthetic pathways on endothelial cell metabolism.
- To utilize 13C metabolic flux analysis (13C MFA) to quantify changes in metabolic networks within endothelial cells.
- To assess the role of glutamine and the malate shuttle in endothelial metabolism under inhibited pathway conditions.
Main Methods:
- Employed stable isotope labeling with 13C metabolic flux analysis (13C MFA).
- Developed a baseline 13C MFA model for HUVECs using glucose, glutamine, and a four-carbon input.
- Administered targeted metabolic inhibitors: fidarestat (polyol pathway), DHEA (pentose phosphate pathway), and azaserine (hexosamine biosynthetic pathway).
Main Results:
- Observed significantly increased glutamine uptake in fidarestat- and azaserine-treated HUVECs.
- Fidarestat and DHEA treatments led to decreased 13C enrichment in glycolytic, TCA cycle metabolites, and amino acids.
- Azaserine treatment primarily affected UDP-GlcNAc enrichment, with 13C MFA indicating increased pentose phosphate pathway and TCA activity.
Conclusions:
- Targeted inhibition of glycolytic side branch pathways profoundly alters the endothelial metabolic network.
- Endothelial malate shuttle activity appears to be significant and can be modulated by pathway inhibition.
- Further research is needed to understand the systemic metabolic consequences of targeted metabolic therapies for cardiovascular disease.
